Burnstock G (1972) Purinergic nerves. Pharmacol Rev 24(3):509–581

CAS  PubMed  Google Scholar 

Ralevic V, Burnstock G (1998) Receptors for purines and pyrimidines. Pharmacol Rev 50(3):413–492

CAS  PubMed  Google Scholar 

Burnstock G, Knight GE (2004) Cellular distributions and functions of P2 receptor subtypes in different systems. Int Rev Cytol 240:31–304

CAS  PubMed  Article  Google Scholar 

Burnstock G (2016) Short- and long-term (trophic) purinergic signaling. Philos Trans R Soc B 371(1700):20150422

Article  Google Scholar 

Huang Z, Xie N, Illes P, Di Virgilio F, Ulrich H, Semyanov A, Verkhratsky A, Sperlagh B, Yu SG, Huang C, Tang Y (2021) From purines to purinergic signalling: molecular functions and human diseases. Signal Transduct Target Ther 6(1):162

CAS  PubMed  PubMed Central  Article  Google Scholar 

ClinicalTrials.gov. National Library of Medicine (US) Bethesda. https://clinicaltrials.gov/. Accessed 5 March 2022

EU Clinical Trials Register. https://www.clinicaltrialsregister.eu/. Accessed 5 March 2022

Abdulqawi R, Dockry R, Holt K, Layton G, McCarthy BG, Ford AP, Smith JA (2015) P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomized, double-blind, placebo-controlled phase 2 study. Lancet 385(9974):1198–1205

CAS  PubMed  Article  Google Scholar 

Martinez FJ, Afzal AS, Smith JA, Ford AP, Li JJ, Li Y, Kitt MM, Chronic cough in IPF Study Group (2021) Treatment of persistent cough in subjects with idiopathic pulmonary fibrosis (IPF) with Gfapixant, a P2X3 antagonist, in a randomized, placebo-controlled clinical trial. Pulm Ther 7(2):471–486

PubMed  PubMed Central  Article  Google Scholar 

Fletcher MC (2022) Selectivity of the P2X3 receptor antagonist Eliapixant, and its potential use in the treatment of endometriosis. Purinergic Signal 18(1):1–3

CAS  PubMed  PubMed Central  Article  Google Scholar 

Gilbert SM, Baird AG, Glazer S, Barden JA, Glazer A, Teh LC, King J (2017) A phase I clinical trial demonstrates that nfP2X7-targeted antibodies provide a novel, safe and tolerable topical therapy for basal cell carcinoma. Br J Dermatol 177:12–13

Article  Google Scholar 

Stock TC, Bloom BJ, Wei N, Ishaq S, Park W, Wang X, Gupta P, Mebus CA (2012) Efficacy and safety of CE-224.535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J Rheumatol 39(4):720–727

CAS  PubMed  Article  Google Scholar 

Diaz VAJ, Tello-Montoliu A, Moreno R, Gonzalez IG, Alonso JAB, Romaguera R, Navarro EM, Salvadores PJ, Galan EP, De Miguel CA, Fernandez GB, Saez AO, Barbeira SF, Roubin SR, Miguez JO, Penaranda AS, Chavarri MV, Fillat AC, Iglesias FC, Romo AI (2019) Assessment of platelet REACtivity after transcatheter aortic valve replacement: the REACTAVI Trial. JACC Cardiovasc Interv 12(1):22–32

Article  Google Scholar 

Park JB, Koo BW, Choi WG, Kim SY, Park J, Kwan J, Park CG, Kim HS (2013) Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicentre, randomized, open-label, phase IV, noninferiority trial. Clin Ther 35(1):28–37

CAS  PubMed  Article  Google Scholar 

Kim CJ, Park MW, Kim MC, Choo EH, Hwang BH, Lee KY, Choi YS, Kim HY, Yoo KD, Jeon DS, Shin ES, Jeong YH, Seung KB, Jeong MH, Yim HW, Ahn Y, Chang K, TALOS-AMI investigators (2021) Unguided de-escalation from ticagrelor to clopidogrel in stabilized patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI_: an investigator-initiated, open-label, multicentre, non-inferiority, randomized trial. Lancet 398(10308):1305–1316

CAS  PubMed  Article  Google Scholar 

Lee S, Lee H, Park KW, Kang HJ, Koo BK, Kim HS, Choi D, Kim M, Oh BH (2013) Comparison of antiplatelet effect and safety of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients: multi-centre, randomized, double-blind, phase IV, non-inferiority clinical trial. Am J Cardiovasc Drugs 13(6):413–424

PubMed  Article  Google Scholar 

Tam CC, Kwok J, Wong A, Yung A, Shea C, Kong SH, Tang WH, Siu D, Chan R, Lee S (2017) Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome. J Int Med Res 45(1):134–146

CAS  PubMed  Article  Google Scholar 

Steblovnik K, Blinc A, Mijovski MB, Fister M, Mikuz U, Noc M (2016) Ticagrelor versus Clopidogrel in comatose survivors of out-of-hospital cardiac arrest undergoing percutaneous coronary intervention and hypothermia. Circulation 134(25):2128–2130

PubMed  Article  Google Scholar 

Seo K, Tahk S, Yang H, Yoon M, Shin J, Choi S, Lim H, Hwang G, Choi B, Park J, Shin J, Lee Y, Choi Y, Park S, Jin X (2014) Point-of-care measurements of platelet inhibition after clopidogrel loading in patients with acute coronary syndrome: comparison of generic and branded clopidogrel bisulfate. Clin Ther 36(11):1588–1594

CAS  PubMed  Article  Google Scholar 

Li H, Guo J, Carlson GF, Teng R (2016) Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease. Br J Clin Pharmacol 82(2):352–361

CAS  PubMed  PubMed Central  Article  Google Scholar 

Natale P, Palmer SC, Saglimbene VM, Ruospo M, Razavian M, Craig JC, Jardine MJ, Webster AC, Strippoli GF (2022) Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev 2(2):CD008834

PubMed  Google Scholar 

Liu PY, Su CH, Kuo FY, Lee WL, Wang YC, Lin WS, Chu PH, Lu TM, Lo PH, Lee CH, Lan WR, Huang CL, Tsukiyama S, Yang WC, Cheng LC, Rafael V, Nikolajsen C, Yin WH (2022) Prasugrel switching from clopidogrel after percutaneous coronary intervention for acute coronary syndrome in Taiwanese patients: an analysis of safety and efficacy. Cardiovasc Interv Ther 37(2):269–278

CAS  PubMed  Article  Google Scholar 

Sweeny JM, Angiolillo DJ, Franchi F, Rollini F, Waksman R, Raveendran G, Dangas G, Khan ND, Carlson GF, Zhao Y, Teng R, Mehran R (2017) Impact of diabetes mellitus on the pharmacodynamic effects of ticagrelor versus clopidogrel in troponin-negative acute coronary syndrome patients undergoing ad hoc percutaneous coronary intervention. J Am Heart Assoc 6(4):e005650

PubMed  PubMed Central  Article  Google Scholar 

Price MJ, Walder JS, Baker BA, Heiselman DE, Jakubowski JA, Logan DK, Winters KJ, Li W, Angiolillo DJ (2012) Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial. J Am Coll Cardiol 59(25):2338–2343

CAS  PubMed  Article  Google Scholar 

Pourdjabbar A, Hibbert B, Chong AY, Le May MR, Labinaz M, Simard T, Ramirez FD, Lugomirski P, Maze R, Froeschl M, Glover C, Dick A, Marquis JF, Bernick J, Wells G, So DYF, CAPITAL Investigators (2017) A randomized study for optimizing crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome The CAPITAL OPTI-CROSS Study. Thromb Haemost 117(2):393–310

Google Scholar 

Franchi F, Rollini F, Rivas J, Rivas A, Agarwal M, Briceno M, Wali M, Nawaz A, Silva G, Shaikh Z, Maailiki N, Been L, Pineda AM, Suryadevara S, Soffer D, Zenni MM, Bass TA, Angiolillo DJ (2020) Prasugrel versus ticagrelor in patients with CYP2C19 loss-of-function genotypes: results of a randomized pharmacodynamic study in feasibility investigation of rapid genetic testing. JACC Basic Transl Sci 5(5):419–428

PubMed  PubMed Central  Article  Google Scholar 

Jeong YH, Oh JH, Yoon HJ, Park Y, Suh J, Lee SW, Lee K, Kim JS, Chun WJ, Park YH, Nam CW, Kim JH, Ahn JH, Hwang SJ, Hwang JY, Tantry US, Gurbel PA, Shin ES (2021) Pharmacodynamic profile and prevalence of bleeding episode in East Asian patients with acute coronary syndromes treated with prasugrel standard-dose versus de-escalation strategy: a randomized A-MATCH trial. Thromb Haemost 121(1):1376–1386

PubMed  Article  Google Scholar 

Waksman R, Maya J, Angiolillo DJ, Carlson GF, Teng R, Caplan RJ, Ferdinand KC (2015) Ticagrelor versus clopidogrel in Black patients with stable coronary artery disease: prospective, randomized, open-label, multiple-dose, crossover pilot study. Circ Cardiovasc Interv 8(7):e002232

PubMed  Article  Google Scholar 

Reisman AM, Robbins BT, Chou DE, Yugrakh MS, Gross GJ, Privitera L, Nazif T, Sommer RJ (2018) Ticagrelor for refractory migraine/ patent foramen ovale (TRACTOR): an open-label pilot study. Neurology 91(22):1010–1017

CAS  PubMed  Article  Google Scholar 

Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T, Orban M, Hadamitzky M, Merkely B, Kiss RG, Komocsi A, Dezsi CA, Holdt L, Felix SB, Parma R, Klopotowski M, Schwinger RHG, Rieber J, Huber K, Neumann FJ, Koltowski L, Mehilli J, Huczek Z, Massberg S (2017) Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomized, open-label, multicentre trial. Lancet 390(10104):P1747-1757

Article  Google Scholar 

Gasecka A, Nieuwland R, van der Pol E, Hajji N, Cwiek A, Pluta K, Konwerski M, Filipiak KJ (2019) P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets. Cardiol J 26(6):782–789

PubMed  Article  Google Scholar 

Zafar MU, Baber U, Smith DA, Sartori S, Contreras J, Rey-Mendoza J, Linares-Koloffon CA, Escolar G, Mehran R, Fuster V, Badimon JJ (2017) Antithrombotic potency of ticagrelor versus clopidogrel in type-2 diabetic patients with cardiovascular disease. Thromb Haemost 117(10):1981–1988

PubMed  Article  Google Scholar 

Lozano I, Rumoroso JR, Perez de Prado A, Moreno R, Hernandez F (2021) Antiplatelet therapy after stenting at the crossroads: easiest or personalized therapy? JACC Cardiovasc Interv 14(8):929–930

PubMed  Article  Google Scholar 

Lhermusier T, Lipinski MJ, Drenning D, Marso S, Chen F, Torguson R, Waksman R (2014) Switching patients from clopidogrel to prasugrel in acute coronary syndrome: impact of the clopidogrel loading dose on platelet reactivity. J Interv Cardiol 27(4):365–372

PubMed  Article  Google Scholar 

Franchi F, Rollini F, Rios JR, Rivas A, Agarwal M, Kureti M, Nagaraju D, Wali M, Shaikh Z, Briceno M, Nawaz A, Moon JY, Been L, Suryadevara S, Soffer D, Zenni MM, Bass TA, Angiolillo DJ (2018) Pharmacodynamic effects of switching from ticagrelor to clopidogrel in patients with coronary artery disease: results of the SWAP-4 Study. Circulation 137(23):2450–2462

CAS  PubMed  Article  Google Scholar 

Ariotti S, Ortega-Paz L, van Leeuwen M, Brugaletta S, Leonardi S, Akkerhuis KM, Rimoldi SF, Janssens G, Gianni U, van den Berge JC, Karagiannis A, Windecker S, Valgimigli M, HI-TECH Investigators (2018) Effects of ticagrelor, prasugrel, or clopidogrel in endothelial function and other vascular biomarkers: a randomized crossover study. JACC Cardiovasc Interv 11(16):1576–1586

PubMed  Article